Get the Stockscreener App
3.91
4.17%
-0.17
After Hours:
3.96
0.05
+1.28%
Precigen Inc stock is traded at $3.91, with a volume of 4.31M.
It is down -4.17% in the last 24 hours and up +1.56% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$4.08
Open:
$4.12
24h Volume:
4.31M
Relative Volume:
0.48
Market Cap:
$1.17B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-10.03
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+10.76%
1M Performance:
+1.56%
6M Performance:
+155.56%
1Y Performance:
+317.20%
1-Day Range:
$3.85
$4.18
1-Week Range:
$3.39
$4.24
52-Week Range:
$0.6513
$5.225
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
3.91 | 1.44B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.90 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.74 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
814.17 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
313.54 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Tools to assess Precigen Inc.’s risk profileEarnings Miss & Long-Term Growth Stock Strategies - newser.com
How to integrate Precigen Inc. into portfolio analysis toolsStop Loss & Real-Time Volume Surge Alerts - newser.com
Real time social sentiment graph for Precigen Inc.July 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Earnings visualization tools for Precigen Inc.2025 AllTime Highs & Risk Controlled Stock Alerts - newser.com
How Precigen Inc. stock performs in high volatility marketsVolume Spike & Weekly High Momentum Picks - newser.com
What technical models suggest about Precigen Inc.’s comebackOil Prices & Free Risk Controlled Daily Trade Plans - newser.com
Analyzing net buyer seller activity in Precigen Inc.July 2025 Trade Ideas & Safe Entry Point Alerts - newser.com
How to monitor Precigen Inc. with trend dashboardsEarnings Miss & High Return Trade Opportunity Guides - newser.com
Is now a turning point for Precigen Inc.Trade Performance Summary & Weekly Top Stock Performers List - newser.com
Why Precigen Inc. stock appeals to dividend seekersEarnings Growth Report & Trade Opportunity Analysis Reports - newser.com
Can Precigen Inc. stock deliver strong Q4 earningsJuly 2025 Macro Moves & Trade Opportunity Analysis - nchmf.gov.vn
Will Precigen Inc. stock deliver long term returnsPortfolio Value Summary & Growth-Oriented Investment Plans - nchmf.gov.vn
Precigen Stock Surges Amid Promising Clinical Trial Outcomes - timothysykes.com
Why Precigen Inc. stock is seen as undervaluedTrade Performance Summary & Risk Managed Investment Entry Signals - nchmf.gov.vn
A Look at Precigen (PGEN) Valuation After PAPZIMEOS’ Full FDA Approval and Clinical Breakthroughs - Sahm
What analyst consensus says on Precigen Inc. stockQuarterly Trade Report & Consistent Profit Trading Strategies - nchmf.gov.vn
Pharma News: What dividend safety score for Precigen Inc. stock2025 Trade Ideas & Reliable Volume Spike Trade Alerts - nchmf.gov.vn
Precigen, Inc. (PGEN) Stock Analysis: Unlocking a 136% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis - Yahoo Finance
Precigen, Inc. Hits Day High with 10.31% Surge in Strong Intraday Performance - Markets Mojo
Patient Capital's Q3 2025 Top Contributors And Detractors - Seeking Alpha
Minimal Residual Disease Pipeline 2025: Pioneering Clinical Developments by 8+ Global Innovators – DelveInsight | Highlighting Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc - Barchart.com
Will a bounce in Precigen Inc. offer an exitGap Up & Fast Entry Momentum Trade Alerts - newser.com
Precigen Inc83% of Responders Show Continued Complete Response After 36 Months - 富途牛牛
Precigen Inc (I5X.SG) stock price, news, quote and history - Yahoo
3 High Growth Stocks With Strong Insider Ownership - simplywall.st
Institutional scanner results for Precigen Inc.July 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
PGEN SEC FilingsPrecigen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Precigen Says Drug for Rare Respiratory Disease Shows Durable Outcomes - MarketScreener
Precigen reports durable responses to RRP treatment in long-term data - Investing.com Canada
Precigen reports durable responses to RRP treatment in long-term data By Investing.com - Investing.com South Africa
Precigen (PGEN) Showcases Promising Results for PAPZIMEOS in Tre - GuruFocus
83% of Complete Responders Ongoing at 36 Months — Precigen's PAPZIMEOS Shows Durable Responses - Stock Titan
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis - Yahoo Finance
Precigen, Inc.Common Stock (NQ: PGEN - FinancialContent
Using flow based indicators on Precigen Inc.Market Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):